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Abstract
Background: The existence nematodes of veterinary importance such as Haemonchus contortus resistant to
anthelmintic drugs, including the macrocyclic lactones, has become a major concern in animal health. Macrocyclic
lactone resistance in H. contortus seems to be multigenic including the active efflux of these drugs by P-glycoproteins,
members of the ABC transporter family, present in this parasite. The goals of the present work were to determine the
activity of H. contortus P-glycoprotein 9.1 (Hco-PGP-9.1) and its interaction with the avermectins, ivermectin, abamectin,
and also the milbemycin, moxidectin. Additionally, the localisation of Hco-PGP-9.1 was sought in adult worms.
Methods: Hco-Pgp-9.1 was cloned and expressed in mammalian cells and its expression profile was determined at the
transcriptional and protein level by qRT-PCR and Western-blot, respectively. The nematode transport activity was
assessed using the tracer dye Rhodamine 123. A ligand competition assay between different macrocyclic lactones and
Rhodamine 123 was used to establish whether or not there was interaction between Hco-PGP-9.1 and the avermectins
(abamectin and ivermectin) or moxidectin. In addition, immunostaining was carried out to localise Hco-PGP-9.1
expression in the transgenic cells and in adult female parasites.
Results: Hco-PGP-9.1 was expressed in the cell membrane of the transfected host cells and was able to extrude
Rhodamine 123. Ivermectin and abamectin, but not moxidectin, had a pronounced inhibitory effect on the ability of
Hco-PGP-9.1 to transport Rhodamine 123. Antibodies raised against Hco-PGP-9.1 epitopes localised to the uterus of
adult female H. contortus.
Conclusions: These results suggest a strong interaction of the avermectins with Hco-PGP-9.1. However, possibly due to
its physico-chemical properties, moxidectin had markedly less effect on Hco-PGP-9.1. Because of the greater interaction
of the avermectins than moxidectin with this transporter, it is more likely to contribute to avermectin resistance than to
moxidectin resistance in H. contortus. Possible over expression of Hco-PGP-9.1 in the female reproductive system in
resistant worms could reduce paralysis of the uterus by macrocyclic lactones, allowing continued egg release in drug
challenged resistant worms.
Keywords: Macrocyclic lactone resistance, P-glycoprotein, Transport studies, Heterologous expression system, Protein
localisation, Ivermectin, Abamectin, Moxidectin
Background
Anthelmintic resistance (AR) in gastro-intestinal (GI)
nematodes such as Haemonchus contortus, has become a
serious problem for livestock industries. In small rumi-
nants, H. contortus can significantly decrease flock pro-
duction [1]. The primary means of parasite control in
animal health is through anthelmintic drugs, of which, the
macrocyclic lactones (MLs) are widely used, with activity
against both ecto- and endoparasites [2]. Ivermectin
(IVM), the first ML anthelmintic commercially developed,
is a chemically modified product from Strepmomyces aver-
mitilis fermentation [3]. The MLs have two subclasses:
one corresponding to the avermectins, such as IVM, aba-
mectin (ABA), doramectin (DOR), eprinomectin (EPR),
selamectin (SEL) [4] which are used to control nematodes
and some ectoparasites in animals. IVM is also used in
humans. Emamectin (EMC) is used in fish farming to con-
trol sea lice [5]. The other group corresponds to the mil-
bemycins including moxidectin (MOX) and milbimycin
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oxime (MO), used against parasitic nematodes in farm
and companion animals [6–8]. The MLs act by binding
irreversibly to glutamate-gated chloride channels
(GluCls), which are present in invertebrates such as
nematodes, producing a flaccid muscular paralysis [9].
Structurally the MLs have a macrocyclic lactone ring
based in a benzofuran core [10] but have some differ-
ences, notably the attached disaccharide moiety at the
C-13 of the ML ring present in the avermectins but not
on the milbemycins [11]. In addition, the milbemycin,
MOX has a methoxime at C-23 and an olefinic side
chain at C-25, which are not present in the avermectins
[2]. The use of the ML in veterinary medicine has been
the anchor strategy to control parasitic pathogens but
also in the case of IVM, has been applied successfully to
control human parasitoses such as river blindness dis-
ease caused by Onchocerca volvulus [12]. Despite the re-
markable ML efficacy, parasitic nematodes have
developed resistance to these drugs, limiting their para-
siticidal effect [13, 14]. In large animal nematodes such
as H. contortus, ML resistance has been reported in field
isolates and experimentally selected strains [15–18]. ML
resistance in nematodes has a genetic basis involving
several genes turning into a complex process not com-
pletely understood [2]. One of the mechanisms
hypothesised to be participating in ML resistance in
nematodes is possibly the active transport of these drugs
by the ATP-Binding-Cassette (ABC) transporters such
as P-glycoprotein (PGP) [19]. ABC transporters are cell-
membrane proteins that transport across the mem-
brane, a wide range of structurally unrelated substrates,
including anthelmintics such as IVM [20]. In nema-
todes, including H. contortus and the free-living model
Caenorhabditis elegans, an up-regulation of ABC trans-
porters that has a direct correlation with a ML resist-
ance phenotype has been reported [21, 22]. Moreover,
in H. contortus some P-gps have been reported to be
over-expressed in IVM field resistance strains, including
Hco-Pgp-2 or A [21–23] and also Hco-Pgp-9 or E [23].
Recently, the H. contortus genome has been fully se-
quenced, describing at least 10 Hco-Pgp genes among
the ABC transporters present in this parasite [24]. In H.
contortus, three copies of Hco-Pgp-9 gene (Hco-Pgp-9.1,
Hco-Pgp-9.2 and Hco-Pgp-9.3) have now been partially
identified [24], with expression of the Hco-Pgp-9.1 tran-
script, previously termed Hco-Pgp-E [23], being reported
to be up-regulated in ML selected and field resistant
strains of H. contortus [23]. Regarding orthologs in other
trichostrongylids from ruminants, an up-regulation of Tci-
pgp-9 in all life-cycle stages of the sheep nematode Tela-
dorstagia circumcinta in IVM resistant isolates has been
described [25]. In another helminth from cattle, Cooperia
onchophora an up-regulation of the ortholog Con-pgp-9 in
an IVM selected strain was also described [26].
Due to this data showing an over-expression of Hco-
Pgp-9.1, and its orthologs, in H. contortus and other
nematodes with veterinary importance resistant to ML,
as well as the strong interaction described between Hco-
PGP-2 and the avermectins, suggesting a nematode
transporter involvement in ML resistance in H. contor-
tus [27], the aim of the present work was to characterise
the Hco-PGP-9.1 transport activity and its interaction
with the MLs, in order to ascertain its possible involve-
ment in the resistance to these drugs. In addition, Hco-
PGP-9.1 expression and localisation in the adult stage of
this parasite was investigated.
Methods
Ethics statement
Animals and standard operating procedures (SOPs) used
in this research study were approved (Protocol #3845)
and adhered to the guidelines from the Animal Care
Committee of McGill University.
Worms
Adult H. contortus from the laboratory PF23 isolate, sus-
ceptible to the MLs [15], were used. Worms were col-
lected from the abomasum of sheep and incubated in
PBS (phosphate-buffer saline) for 2 h at 37 °C.
Cells and reagents
An aliquot of adherent parental LLC-PK1 cells (pig kidney
epithelium) and a transgenic cell line over-expressing the
mdr1a gene (mouse PGP) called mdr1a/LLC-PK1 as posi-
tive control for transport studies, were gifts from Dr. A.
H. Schinckel (The Netherlands Cancer Institute, The
Netherlands). HBSS media, 199 media, Lipofectamine
2000®, G418, penicillin/streptomycin, TOP10F’competent
cells, Trizol®, pcDNA 3.1(+) mammalian expression vector,
Rhodamine 123; secondary antibodies Alexa fluor 488®,
Alexa fluor 633 F(ab’)2, DAPI (4′,6-diamidino-2-phenyl-
dole) staining and the BCA protein assay kit were pur-
chased from Thermo Fischer Scientific (Burlington, ON,
Canada). RNeasy® kit, Omniscript® reverse-transcription
kit, and SYBR Green were obtained from Qiagen (Hilden,
Germany). Subcloning vector pGMET-Easy was from Pro-
mega (Madison, WI, USA). Restriction enzymes BamH I
and Not I were from New England Biolabs (Ipswich, MA,
USA). MOX was a kind gift from Wyeth (Fort Dodge
Animal Health, Madison, NJ, USA). IVM and ABA
and all the listed chemicals were from Sigma-Aldrich
(Burlington, ON, Canada). SDS-PAGE and Western-
blot reagents were from BIO-RAD (Hercules, CA,
USA). The chemiluminescence kit was from GE Life
Sciences (Mississauga, ON, Canada).
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RNA extraction
Worms were homogenised and lysed with the Trizol® re-
agent according to the manufacturer’s instruction. The
RNA pellet obtained was dried and eluted in 50 μl of RNase
free water. RNA quantification was measured in a nano-
photometer IMPLEN® (Westlake Village, CA, USA) at
260 nm wavelength. All extracted RNA was kept at -80 °C.
Reverse transcription polymerase chain reaction (RT-PCR)
Total RNA (1 μg) was reverse transcribed using the
Omniscript® reverse transcription kit following the man-
ufacturer’s protocol. Synthesised cDNA was stored at–
20 °C for further use.
Amplification and cloning of the full length H. contortus
Hco-Pgp-9.1 cDNA sequence
H. contortus P-glycoprotein-9.1 DNA sequence was from
([28], Additional file 1). Specific primers to amplify the
full-length sequence were designed using Geneious
bioinformatics software, version 5.5.6 (Biomatters Ltd,
Auckland, New Zealand). The cloning strategy was to ligate
the Hco-Pgp-9.1 cDNA sequence and the linearised
pcDNA3.1 (+) mammalian expression vector using restric-
tion sites. To carry this out, the primers used were: forward
primer 5′-aagttagggatcccCaccATGGGCTTTTTGAAGA
ACGG-3′ including a specific sequence for pcDNA3.1 (+)
in small case, then a BamH I restriction site (underlined
in small case), after a Kozak sequence, around the start
codon, both in bold [29].
Reverse primer 5′-agacctagcggccgcTCATCCCTTGGC
CAATGTTTGCTT-3′, included a Not I restriction site
(in bold small case), then a stop codon (underlined as
above). A PCR with these primers was run. After confirm-
ation that the expected amplicon was present, the PCR
product was ligated into pGEM-T® Easy subcloning vec-
tor. Furthermore, the cloned sequence was digested indi-
vidually with each restriction enzyme referred above, and
ligated into pcDNA 3.1(+) mammalian expression vector
using the same restriction sites.
Transformation was carried out in E. coli TOP10F’
competent cells. After, positive colonies were screened
by colony PCR and restriction digestion analysis. DNA
extracted from positive transformants was digested with
BamHI and Not I, confirming the construct ligation and
these DNA plasmids were sent for sequencing at Gen-
ome Quebec Innovation Centre (McGill University, QC,
Canada) to confirm the specific Hco-Pgp-9.1 full-length
cDNA sequence.
Stable transfection in mammalian cells
For stable transfection the mammalian porcine cell line
LLC-PK1 was used [27]. Original LLC-PK1 parental cells
were seeded on 24 well plates (2 × 105 cells/well) and
grown in 199 medium supplemented with 10 % fetal calf
serum and penicillin/streptomycin (100 units/ml;
100 μg/ml, respectively). Cells close to 100 % confluency
were transfected using 18 μg of plasmid DNA using Lipo-
fectamine 2000®, following the manufacturer’s instruc-
tions. In parallel, as a positive control for transfection, the
Chloramphenicol Acetyl Transferase (CAT) gene was
transfected into these cells. Twenty-four hours after trans-
fection, medium was removed and replaced with supple-
mented 199 medium. Forty-eight hours after transfection,
the cells were washed, collected and counted in order to
seed them to 25 % confluency in 24 well plates under se-
lection pressure of G418 or neomycin (Geneticin®) at
400 mg/l.
After several weeks of selection, stable transfected col-
onies were collected individually and transferred to new
culture flasks. Each individual colony was assessed for




RNA was extracted from stable transfectants using the
RNeasy extraction kit, following the manufacturer’s in-
structions as above. Subsequently, a reverse transcription-
PCR was done with the extracted RNA. Then, the synthe-
sised cDNA was used as template for a qRT-PCR with
specific primers (see Table 1) for Hco-Pgp-9.1 and the pig
mdr1 (GenBank accession number XM_003130205.3). Pig
GAPDH (Glyceraldehyde-3 phosphate dehydrogenase)
was used as a housekeeping gene for normalisation
(GenBank accession number NM_001206359.1). After
serial dilution of the cDNA template, a qRT-PCR was
carried out using SYBER Green in a Rotor-Gene ther-
mal cycler (Qiagen, Hilder, Germany) with the follow-
ing conditions: initial hold at 95 °C for 15 min, then
40 cycles including: 94 °C for 15 s; 57 °C for 30 s for
annealing and 72 °C for 1 min final extension. Subse-
quently, a melting curve analysis was done for all the
amplified PCR products. Primers for target and
housekeeping genes were run in four replicates. After
every qRT-PCR run, data were analysed and the effi-
ciency of the reaction estimated according to [30].
Table 1 Primers for qRT-PCR (quantitative Real-Time-PCR) on
Haemonchus contortus P-glycoprotein-9.1/epithelial-like pig (Sus
scorfa) kidney cell (Hco-Pgp-9.1/LLC-PK1) transfected cells
Primer name Nucleotide sequence (5′–3′)
Hco-Pgp-9.1 (forward) GGC CTC AGT TTG CTG TTC TC
Hco-Pgp-9.1 (reverse) ATC TGG TCG CGT TGG ATA AG
Sus scorfa GAPDH (forward) AAC TGC TTG GCA CCC CTG
Sus scorfa GAPDH (reverse) TTG GCA GCG CCG GTA GAA
Sus scorfa mdr1 (forward) TGC CAC CAC GAT AGC TGA GAA CAT
Sus scorfa mdr1 (reverse) ATG GCG ATT CTC TGC TTC GTC CA
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Relative expression of Hco-Pgp-9.1 over the endogen-
ous pig mdr1 was obtained based on the 2ΔΔ Ct
method.
Protein profile: membrane enrichment fraction
Hco-Pgp-9.1/LLC-PK1 transfected cells were grown in
75 cm2 flasks close to 100 % confluency. Cells were col-
lected with a scraper, counted and re-suspended in buffer
containing protease inhibitors (1X PBS pH 7.4; 1 mM
PMSF; 1 mM EGTA; 10 μg/ml Leupeptin; 1 μg/ml Pepsta-
tin A). Cells were then washed twice with a solution con-
taining 1X PBS + 1 mM DTT+ 1 mM PMSF to a volume
of 50 ml. Then the cell suspension was divided into two
tubes (25 ml volume each) and centrifuged at 1000× g for
15 min at 4 °C. Afterwards, each pellet was re-suspended
in an appropriate volume of buffer containing 1X PBS +
1 mM DTT+ 1 mM PMSF. Cells were then sonicated 3
times for 10 s using 40 % amplitude. Subsequently, cell
pellets were centrifuged at 1400× g for 15 min at 4 °C. Su-
pernatants were carefully collected and combined in a sin-
gle tube. This sample was ultra-centrifuged at 135 000× g
for 60 min at 4 °C. The supernatant was discarded and the
pellet re-suspended in 2.5 ml of a solution containing 1X
PBS + 1 mM DTT + 1 mM MgCl2. Finally, the protein
concentration from isolated membranes was quantified by
the BCA protein assay method and kept at–80 °C.
In parallel, an aliquot of whole crude membrane from H.
contortus worms was isolated. Fifty H. contortus adult
worms (females and males) were homogenised in buffer
containing PBS 1× pH 7.4; 1 mM PMSF; 1 mM EGTA;
10 μg/ml Leupeptin and 1 μg/ml Pepstatin A. The solution
was centrifuged at 45 000× g for 15 min at 4 °C, the super-
natant was recovered and centrifuged again at 45 000× g
for 15 min at 4 °C. The supernatant was carefully recov-
ered and sonicated 3 times for 10 s with 40 % amplitude.
Finally, the sample was ultracentrifuged at 135 000× g for
60 min at 4 °C, the pellet was recovered and re-suspended
in PBS + 1 mM DTT+ 1 mM MgCl2 + 0.5 % Triton X-100
for further protein quantitation by the BCA protein assay
method. Samples were kept at–80 °C until further separ-
ation on SDS-PAGE.
Hco-PGP-9.1 antibody preparation and Western blot
Peptide antigens were selected from the H. contortus PGP-
9.1 amino acid sequence, analysed, synthesised commer-
cially and used to immunise rabbits by 21st Century Bio-
tech. Inc. (Marlborough, MA, USA) (see Additional file 1).
The specificity of purified Hco-PGP-9.1 peptide epitopes
was determined by ELISA and dot blot. A mixture 1:1 of
both antibodies for each antigen peptides for Hco-PGP-9.1
was used for further Western-blot and immunolocalisa-
tion. Membrane protein fractions previously obtained
from Hco-Pgp-9.1/LLC-PK1, CAT/LLCPK1 control cells
and H. contortus worms whole crude membrane extracts,
from a mixed population of female and male adult worms,
were separated in a 4.5–10 % polyacrylamide gradient gel.
Proteins were transferred, by the semi-dry system, to a
PVDF membrane at 25 volts for 25 min. The membrane
was blocked overnight at 4 °C in 5 % skim milk blocking
solution with 0.05 % Tween-20®. Then the membrane was
washed thoroughly in TBS-0.05 % Tween-20®. The mem-
brane was then incubated, overnight at 4 °C, with anti-
Hco-PGP-9.1 antibody, at 1/500 dilution.
After several washes, the membrane was incubated with
anti-rabbit secondary antibody conjugated to horseradish
peroxidase in a 1/5000 dilution at room temperature for
1 h. After washing, the membrane was developed using a
chemiluminescence kit and X-Omat films.
Immunofluorescence assay (IFA) on Hco-Pgp-9.1/LLC-PK1
transfectants
Hco-Pgp-9.1/LLC-PK1 transfectants were grown on cover-
slips to 70 % confluency. Cells were then fixed with 4 %
paraformaldehyde (PAFOH). The cells were washed and
blocked with 3 % BSA for 1 h at room temperature, and
then washed and incubated with the anti-Hco-PGP-9.1
antibody, or anti-Hco-PGP-9.1 antibody pre-absorbed by
both synthetic peptides (pre-absorbed negative control), at
1/50 dilution overnight at 4 °C in the dark. The cells were
then incubated with Alexa®Fluor 488® secondary antibody
in 1/3000 dilution for 45 min at room temperature in the
dark. Cells were then washed and incubated with nucleic
DAPI medium for 4 min at room temperature in the dark.
Following this, the cells were washed and mounted on a
slide with mounting media and sealed with nail polish.
After overnight incubation, stained cells were examined
under an ECLIPSE Ti inverted epifluorescence microscope
(Nikon, Melville, NY, USA) at λ488nm excitation and
λ519nm emission. Images obtained with different dyes
were merged using ImageJ software (http://imagej.nih.
gov/ij/).
Transport assays in transgenic cells expressing Hco-Pgp-
9.1 with Rhodamine 123 and macrocyclic lactones
In order to measure the nematode transporter activity,
Hco-Pgp-9.1/LLC-PK1 transfected cells were tested with
Rhodamine 123 (Rho123) [11] as substrate for efflux
translocation. Cells were plated in 24 well plates in G418-
free medium until confluent. Then, cells were incubated
in HBSS media, 1 % BSA containing 10 μM Rho123 with
or without increasing concentrations of the endectocides:
IVM, ABA or MOX (0.00625–20 μM). Additionally, the
cyclosporin A analogue, valspodar (VSP or PSC833)
(kindly provided by Novartis Animal Health, Switzerland)
was used, at 5 μM, as a maximum reference inhibitor of
Hco-PGP-9.1 transport function since this compound is a
slow transport substrate for MDR1.
Godoy et al. Parasites & Vectors  (2016) 9:52 Page 4 of 11
All the drugs were dissolved in DMSO and diluted
in HBSS transport media with a final DMSO con-
centration of < 0.2 %. Hco-Pgp-9.1/LLC-PK1 trans-
fected cells were incubated with all the reagents,
including Rho123 for 2 h. After incubation, the
medium was discarded and cells carefully washed
three times with PBS. Finally cells were lysed in
PBS/0.5 % SDS. The lysates were stored at–20 °C
until further analysis.
Fluorescence measurement
The intracellular accumulation of Rho123 was measured
using a FLUOstar Galaxy fluorimeter (BMG LABTECH,
Ortenberg, Germany). The reading parameters for
Rho123 were λmax = 507 nm excitation and λmax =
529 nm emission. The inhibition of the Hco-PGP-9.1
transport function by the MLs was compared against the
maximum effect produced by valspodar [11] and
expressed as percent of total VSP inhibition. Each ex-
periment was repeated using three biological replicates
and each drug concentration was run in triplicate. The
data generated were fitted using GraphPad Prism soft-
ware (Version 6).
Localisation of H. contortus P-glycoprotein-9.1 in adult
worms
The Hco-PGP-9.1 antibody mixture described above was
used for immunolocalisation of Hco-PGP-9.1 expression
in the H. contortus adult stage. Worms were collected and
fixed in 3.7 % (w/v) paraformaldehyde in PBS at 4 °C for
6–12 h. Worms were then washed three times in PBS for
15 min and stored at 4 °C in 0.1 % (w/v) paraformaldehyde
in PBS. Subsequently, worms were incubated overnight at
37 °C in 5 % (v/v) 2-mercaptoethanol, 1 % Triton X-100,
125 mM Tris–HCl pH 6.9, and washed briefly in PBS.
Fixed worms were digested for 6–20 h until complete re-
moval of the cuticle layer, in 120 U/ml collagenase at
37 °C in 1 mM CaCl2, 100 mM Tris–HCl pH 7 [31].
Worms were then washed in PBS and incubated for
72 h at 4 °C with a 1/200–300 dilution of the primary
antibody in PBS containing 0.1 % (w/v) BSA, 0.5 % (v/v)
Triton X-100 and 0.05 % (w/v) sodium azide. Non-specific
binding was removed after several washes in PBS/0.1 %
(v/v) Triton X-100 at 4 °C [32]. Worms were incubated
with the secondary antibody Alexa® Fluor 633 F(ab’)2 far-
red fluorescein goat anti-rabbit in a 1/3000 dilution
at 4 °C for 15–18 h. Worms were washed in PBS
containing 0.1 % (v/v) Triton X-100. Finally, worms
were mounted on slides using mounting medium and
examined under the confocal microscope (laser Bio-
Rad Radiance®2100 MP) at λ632 nm emission and
λ647 nm excitation.
Results
Expression profile of Hco-Pgp-9.1 in transfected cells
The relative expression of Hco-Pgp-9.1 in mammalian
LLC-PK1 cells is shown in Fig. 1. The Hco-Pgp-9.1 tran-
script was expressed at 30 fold the level of endogenous
pig mdr1 present naturally in this porcine origin cell line
at the second passage of these transfectants. The expres-
sion of the Hco-Pgp-9.1 transcript appeared to be de-
creasing by the third passage of the same culture
(although the differences were not statistically signifi-
cant), but the difference compared with the endogenous
pig mdr1 was still large. The expression profile was also
corroborated at the protein profile by Western blot. A
protein band of 130 kDa molecular weight was observed
from membranes extracted from Hco-Pgp-9.1/LLC-PK1
transfectant clones (Fig. 2, lanes A and C). In the whole
crude membranes extracted from H. contortus adult
worms (lane B), a similar 130 kDa band and a higher mo-
lecular size band close to 180 kDa were seen. The protein
band of 130 kDa identified in transfected cells may corres-
pond to the unglycosylated form of Hco-PGP-9.1, whereas
the whole crude membranes from the adult stage of the
parasite, may contain both unglycolysalted (130 kDa) and
glycosylated (~180 kDa) forms of Hco-PGP-9.1.
The expression of this nematode transporter in the
host cells was also supported by the subcellular localisa-
tion of Hco-PGP-9.1 in the plasma membrane of the
transfected cells (Fig. 3a). Hco-pgp-9.1 transfected cells
exposed to anti-Hco-PGP-9.1 antibody that had been
Fig. 1 qRT-PCR on Hco-Pgp-9.1/LLC-PK1 cells. Hco-Pgp-9.1 transcript
level present in the transfected pig host cells corresponding to cell
culture passages 2 and 3. Relative expression over pig mdr1
endogenous gene, calculated by the 2ΔΔ Ct method using the pig
GADPH transcript as reference. Mean of 4 technical replicate
experiments for each passage ± SD
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pre-absorbed with the epitope peptides (Fig. 3b) did not
show staining in the cell membrane. The CAT/LLC-PK1
control cells (Fig. 3c) exposed to the anti-Hco-PGP-9.1
antibody (not pre-absorbed) showed generalised fluores-
cence in the cytoplasm, possibly consistent with autoflu-
orescence or an interaction with the CAT enzyme
expressed in the control cells. However, these control
cells did not show labelling of the plasma membrane as
in the Hco-Pgp-9.1 transfected cells treated with the
same antibody. A similar generalised fluorescence of the
cytoplasm of CAT transfected cells was previously ob-
served (27), using the same secondary antibody, but a
different primary antibody, suggesting that this general-
ised fluorescence of the CAT transfected cells is non-
specific.
Transport studies of Hco-PGP-9.1
After the Hco-PGP-9.1 expression profile was assessed,
Hco-Pgp-9.1/LLCPK1 transfected cells were subjected to
a Rho123 translocation assay. It was found that Hco-
Pgp-9.1/LLCPK1 transgenic cells accumulated less than
40 % Rho123 fluorescence compared with the control
parental cells (LLC-PK1) and CAT/LLC-PK1 cells
(Fig. 4), indicative of Rho123 efflux by the transfectants
expressing Hco-PGP-9.1. Although Rho123 fluorescence
accumulation was higher in Hco-Pgp-9.1/LLCPK1 trans-
fectants than in positive control cells over expressing
mdr1a (mouse PGP), these fluorescence means are sig-
nificantly lower than in the control LLC-PK1 untrans-
fected cells. Subsequently, a competition assay between
the different MLs and the Rho123 transport by Hco-
PGP-9.1 was run. A pronounced inhibitory effect by the
avermectins (IVM and ABA) on Hco-PGP-9.1 Rho123
transport was found, giving a saturable effect on the in-
hibition of transport of this fluorophore, which was close
to 80 % of the total Rho123 inhibition effect produced
by VSP on Hco-PGP-9.1 (Fig. 5). In contrast, MOX
caused a non-saturable inhibitory effect on the Rho123
transport by Hco-PGP-9.1. This MOX effect contrasts
with the avermectin effects, for both IVM and ABA in
which 0.5 μM produced a maximal inhibition of Rho123
transport corresponding to 80 % of the effect produced
by VSP at 5 μM. In contrast, MOX even at 10 or 20 μM
concentrations, reached only 50 % or less of the maximal
VSP effect (5 μM) on the inhibition of Rho123 transport.
Localisation of Hco-PGP-9.1 in H. contortus adult stage
The same specific antibody was used to try to determine
the localisation of Hco-PGP-9.1 in H. contortus adult
worms. After examining the whole body, a defined signal
corresponding to the reproductive system, particularly at
the level of the uterus, can be found in female worms
(Fig. 6a–d).
Discussion
ML endectocides represent the cornerstone of current
chemotherapy to control different pathogens such as
ticks, diptera and nematodes [33]. Resistance to these
compounds has arisen particularly in trichostrongylids
such as H. contortus, initially against IVM [34] and later
against ABA and MOX [35, 36]. The involvement of
ABC transporters in ML resistance in nematodes has
been investigated and suggests a linkage between
Fig. 2 Western blot using anti-Hco-PGP-9.1 antibody. Lane (a) Hco-Pgp-
9.1 membrane extracted from Hco-Pgp-9.1/LLC-PK1 transfected cells,
clone 6. Lane (b) whole crude membranes extracted from Haemonchus
contortus adult worms. Lane (c) Hco-Pgp-9.1 membrane extracted
from Hco-Pgp-9.1/LLC-PK1 transfected cells, clone 9. Lane (d) CAT
(Chloramphenicol acetyl transferase)/LLC-PK1 membranes (control cells).
Each lane was loaded with 5 μg of protein
Fig. 3 Immunofluorescence assay (IFA) on Hco-Pgp-9.1 transfected cells (a). Anti-Hco-PGP-9.1 antibody conjugated with fluorescein (AlexaFluor®
488) recognised a strong signal of Hco-PGP-9.1 in the plasma membrane of the host cells (green). b Hco-Pgp-9.1/LLC-PK1 cells incubated with
peptide pre-adsorbed Hco-PGP-9.1 antibody as control. c CAT/LLC-PK1 control cells incubated with anti-Hco-PGP-9.1 antibody. Epifluorescence
microscopy image, magnification: 40X. DAPI stain (blue) of cell nuclei. Scale-bar, 50 μm
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nematode transporters and possible efflux modulation
of the MLs [37–39].
We have investigated the transport activity of Hco-
PGP-9.1 expressed in mammalian cells and its inter-
action with the different MLs. An expression profile of
this transporter was obtained in the transfected cells,
based in its transcript and protein levels in addition to
its localisation in the plasma membrane of the host cells.
The expressed Hco-PGP-9.1 was probably unglycosylated
in the host cells, based on a comparison of the molecu-
lar size of the band seen in Western blots and the pre-
dicted molecular size of the protein. This result is
consistent with the Hco-PGP-2 expression pattern found
in the same mammalian cell line and in whole crude
membranes extracted from H. contortus [27]. Glycosyla-
tion is not required for functional activity of PGPs
expressed in cells [40]. Both the unglycosylated Hco-
PGP-9.1, and the previously characterised unglycosylated
Hco-PGP-2 [27] were able to translocate Rho123.
The protein expression pattern in the porcine cells
was similar to the one previously obtained for Hco-PGP-
2 [27] except that the transcript level of the Hco-pgp-9.1
transgene appeared to decrease by the third passage (the
transcription was not very stable). This is probably
because the Hco-Pgp-9.1 gene, for transfection into the
LLC-PK1 cells, was not codon optimised for the host pig
cells as was Hco-Pgp-2 [27].
When the Hco-PGP-9.1 transport function was
assessed, using the fluorophore probe Rho123, a pro-
nounced reduction of this tracer dye in Hco-Pgp-9.1/
LLC-PK1 transfectants was determined, indicative of an
active transport by Hco-PGP-9.1. Previous work had
pointed out the good substrate characteristics of Rho123
to test nematode transporter activity [28–41]. As shown
in Fig. 5, the avermectins (ABA and IVM) produced a
marked inhibitory effect on the Rho123 efflux by the
Hco-PGP-9.1 transporter. In mammalian models the
interaction of the avermectins with ABC transporters,
has been described with ABA [42] and IVM inhibiting
PGP activity [43] and MRP (Multi-drug Resistant Pro-
tein) activity [44]. This is comparable with the corre-
sponding effect that the avermectins produced on
Rho123 transport inhibition by Hco-PGP-2 [27] and by
mouse PGP [11], confirming a strong interaction of the
avermectins for both nematode and mammalian ABC
transporters. On the other hand, MOX displayed a lower
inhibitory effect on the Rho123 transport by Hco-PGP-
9.1, implying a lesser interaction with this transporter.
These observations are consistent with previous work
describing the interaction of these compounds with Hco-
PGP-2 [27], where the avermectins produced a satur-
ation of the Rho123 transport activity compared with
the inferior effect of MOX on Rho123 transport. These
differences in the interaction with Hco-PGP-9.1, between
the avermectins and MOX, are likely to be due to struc-
tural differences between the ML subgroups. Avermectins,
in contrast to MOX, have a di- (or mono-) saccharide
moiety attached to the C-13 of the macrocyclic ring,
whereas MOX is protonated at this position [2, 45]. This
olaeadrose moiety, in IVM and ABA, is thought to en-
hance the binding of the avermectins to the transporter
[11–27]. On the other hand, MOX, in addition to the ab-
sence of sugar groups attached to the macrocyclic ring,
has other structural features, notably the methoxime
group at the level of the C-23 of the macrocyclic ring,
which may reduce its interaction with nematode trans-
porters. Another aspect which may contribute to this dis-
tinction in the interaction of the MLs with Hco-PGP-9.1,
is a physicochemical characteristic that differs between
the avermectins and MOX. In general, MLs are lipophilic
drugs that need to cross membranes to reach their targets
inside the parasite [20]. In this respect, MOX is more lipo-
philic and has a higher octanol/water coefficient (logp)
than the avermectins [2], perhaps being retained by the
lipid bilayer of the cell membrane. MOX has a longer
half-life than the avermectins inside the host due to its
longer residency in fat tissue [46, 47]. Recently, a nema-
tode PGP from the equine helminth Cylicocylus elongates,
Fig. 4 Functional transport assay using the fluorophore probe
Rhodamine 123 (Rho123). Fluorescence in control cells (untransfected
LLC-PK1, and CAT transfectants); cells over expressing the mouse PGP
(MDR1A– positive control) and the nematode transporter cells (Hco-PGP-
9.1). Results are means of 3 biological replicate experiments ± SD. Analysis
by unpaired, two-tailed t-test showed both the MDR1A and
PGP-9.1 were significantly different from the untransfected LLC-PK1
cells, P < 0.0001 (**)
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termed Ceg-Pgp-9 (ortholog of Ce-Pgp-9), was expressed
in yeast and its interaction, in a competition assay be-
tween the antifungical ketoconazole and MLs, charac-
terised. A strong interaction with the avermectins (IVM
and EPR), and a lesser interaction with MOX, was also
found [48].
Our second objective was to try to localise the expres-
sion of Hco-PGP-9.1 in H. contortus adult worms. In the
free-living nematode C. elegans, its paralogue Cel-Pgp-9,
is predicted to be expressed in the pharynx and intestine
[49]. However in H. contortus, there may be three para-
logs of the Cel-Pgp-9, namely Hco-Pgp-9.1, Hco-Pgp-9.2
and possibly Hco-Pgp-9.3 [24–28]. It was reported that a
differential transcript profile exists between Hco-Pgp-9.2
and Hco-Pgp-9.3 on the one hand, which were reported
to be expressed more abundantly in the L3 stage, and
Hco-Pgp-9.1, which was more abundant in the adult
worm [28]. The primary antibodies were raised to epi-
topes that may be shared, at least between Hco-PGP-9.1
and Hco-PGP-9.2 (see Additional file 1). As a full se-
quence is unavailable for putative Hco-PGP-9.3, we are
unable to assess whether the antibodies may also detect
this putative P-glycoprotein. The anti-PGP-9.1 antibody
labelled the uterus of the female reproductive system. If
there are three paralogues of Pgp-9, each may have a
different function and possible expression profile in the
parasite. Adult female worms possess a developed repro-
ductive tract, including the uterus, which may constitu-
tively express this nematode transporter. The actual
function of Hco-PGP-9.1, possibly in the uterus, is un-
known. From the literature it is well established that in
higher eukaryotes such as mammals, ABC transporters
such as PGP are highly expressed in the apical epithe-
lium membranes including the blood–brain-barrier
[50, 51] and placenta [52, 53], modulating xenobiotic
passage to the central nervous system or from mother
to fetus. It was found that mdr1a (-/-) (ABCB1 knock-
out) adult mice had significantly greater susceptibility
to IVM neurotoxicity than wild-type mice [50]. In the
CF-1 mouse strain carrying a spontaneous mutation
on the mdr1a gene, due to the absence of PGP
expressed in the placenta barrier, IVM induces a con-
genital disorder similar to cleft palate in mouse pups
[54]. In addition, at the level of the placenta, the active
transport of lipophilic molecules such as progesterone,
an important female hormone during pregnancy, has
been described [55]. Our finding of possible Hco-PGP-
9.1 expression in the uterus suggests analogous func-
tions to ABCB1 in mammals, including transport of
xenobiotic products from uterine tissue, or recruitment
Fig. 5 Inhibition by MLs of Rhodamine123 transport in Hco-PGP-9.1 transfected cells. Effect of abamectin (ABA), ivermectin (IVM) and moxidectin
(MOX) compared with the maximum effect displayed by valspodar (VSP), 5 μM. Results are means of three independent biological replicate
experiments ± SD
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of some lipid molecules to complete ova maturation be-
fore release from the female worm through the vulva.
In the context of ML resistance in parasitic nematodes
such as H. contortus, the apparent localisation of Hco-
PGP-9.1 could represent an interesting discovery. It is
well known in the human filarial nematode O. volvulus,
that IVM produces a temporary arrest of microfilaria re-
lease from the female worms [56]. In another filarial spe-
cies, the heartworm of dogs, Dirofilaria immitis, and in
the pig nematode Oesophagostomum dentatum, IVM in-
terferes with embryogenesis in the adult female worms
[57, 58]. Recently, a high expression of GluCl receptors,
such as the avr-14 gene, has been reported in the repro-
ductive system of female and male worms of Brugia
malayi [59]. The localisation of this GluCl may explain
the IVM effects on reproductive tissues. A similar effect
of MLs on the reproductive system of trichostrongylid
nematodes has not been described. However, our data
could suggest a role in which Hco-PGP-9.1, apparently
expressed in the uterus of H. contortus, may be trans-
porting these compounds, thereby protecting this tissue
from the paralysing effect of avermectins on the uterine
muscles and the release of nematode eggs from the fe-
male worm.
Complementary to the possible role of Hco-PGP-9.1 in
ML resistance in H. contortus, there is evidence that
paralogues of Hco-Pgp-9.1, expressed in other veterinary
nematodes, may also be linked to avermectin resistance
[25, 26]. The differences in the interaction of Hco-PGP-
9.1 between the avermectins and MOX, may also explain
the differences observed in the development of resist-
ance to these drugs. ABA, IVM and MOX are among
the most common MLs used in livestock to control
gastro-intestinal helminths [60]. Different studies on
small ruminant farms, have described a reduction in effi-
cacy (<95 %, at the recommended dose rate), mainly to
the avermectins whereas MOX was still effective or
showed a higher efficacy against trichostrongylids, in-
cluding H. contortus [61–63]. Nonetheless resistance to
MOX can arise in gastro-intestinal parasites following
MOX selection pressure [64, 65]. A possible contribu-
tion to the earlier and more common appearance of re-
sistance to the avermectins could be the active efflux of
these compounds by nematode transporters, such as
Fig. 6 Immunolocalisation of Hco-PGP-9.1 in an H. contortus adult female worm. a magnification 20×, Ut: uterus. b magnification 20×, Mw:
muscle wall, Pscoel: pseudocoelom, Ovi: oviduct, Ut: uterus, Int: intestine. c magnification 40×, Ut: uterus. d magnification 40× phase contrast for
image (c). Scale-bars: (a, b), 50 μm; (c, d), 5 μm
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Hco-PGP-9.1, compared with MOX. This could explain
the differences seen in the resistance in the field between
the avermectins and MOX.
Conclusions
The present work has characterised the transport func-
tion of Hco-PGP-9.1, determining its pronounced inter-
action with the avermectins compared with MOX. A
similar pattern of interaction with the MLs was found in
the study of Hco-PGP-2 [27], indicating a possible in-
volvement of nematode transporters in the efflux and
elimination of these drugs from key tissues such as the
uterus and digestive tract, thereby contributing to ML
resistance in H. contortus.
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(GenBank accession number JX430397), Hco-PGP-9.2 (GenBank
accession number: JX430398) and Hco-PGP-9.3 (GenBank accession
number: JX430395). (DOC 37 kb)
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